Medication nonadherence among South American patients with schizophrenia

Objective The objective of this research was to quantify nonadherence to medication and explore the determinants of nonadherence in patients diagnosed with schizophrenia (SZ) from three countries in Latin America (Bolivia, Peru, and Chile). Methods This study was conducted in public mental health centers in Bolivia, Peru, and Chile. The data collected included drug attitude inventory (DAI-10), sociodemographic information, and clinical and treatment characteristics of patients with SZ. Multivariate analysis with multiple linear regression was then performed to identify variables that were potentially associated with the DAI score (dependent variable). Results Two hundred and fifty-three patients diagnosed with SZ participated in the study and 247 fully completed the DAI-10. In the multivariate analysis, medication nonadherence was associated with being a woman (β=−0.16, p=0.029), younger age (β=0.17, p=0.020), younger age at onset of disease (β=−0.17, p=0.019), and lower insight (β=−0.30, p<0.001). Conclusion Being a female, younger age, younger age at onset of disease, and lower insight were the main features associated with nonadherence. If future longitudinal studies confirm these findings, these factors should not be neglected in Latin American mental health public policies to address the problem of nonadherence.

[1]  G. Fond,et al.  Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience , 2017, Social Psychiatry and Psychiatric Epidemiology.

[2]  M. Sajatovic,et al.  Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness , 2017, Patient preference and adherence.

[3]  Mercedes Hernandez,et al.  Families and medication use and adherence among Latinos with schizophrenia , 2017, Journal of mental health.

[4]  K. Baumstarck,et al.  The relationships between patients’ and caregivers’ beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries , 2015, Psychiatry Research.

[5]  Yawen Jiang,et al.  Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization , 2015, Pharmacotherapy.

[6]  R. Kahn,et al.  Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies , 2015, European Neuropsychopharmacology.

[7]  J. van der Vlag,et al.  Role of Heparanase-Driven Inflammatory Cascade in Pathogenesis of Diabetic Nephropathy , 2014, Diabetes.

[8]  J. Haro,et al.  Relationship of Insight with Medication Adherence and the Impact on Outcomes in Patients with Schizophrenia and Bipolar Disorder: Results From A 1-Year European Outpatient Observational Study. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  K. Baumstarck,et al.  Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia , 2013, BMC Psychiatry.

[10]  V. Milanova,et al.  Attitudes Toward Antipsychotic Medication, Insight and Psychopathology in Outpatients with Schizophrenia , 2012, Folia medica.

[11]  E. Lindström,et al.  DAI-10 is as good as DAI-30 in schizophrenia , 2012, European Neuropsychopharmacology.

[12]  J. Maurino,et al.  Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. , 2012, Patient preference and adherence.

[13]  Rafael E. Núñez,et al.  Facing the Sunrise: Cultural Worldview Underlying Intrinsic-Based Encoding of Absolute Frames of Reference in Aymara , 2012, Cogn. Sci..

[14]  A. Loundou,et al.  Insight into illness, neurocognition and quality of life in schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  O. Andreassen,et al.  Predictors of medication adherence in patients with schizophrenia and bipolar disorder , 2012, Acta psychiatrica Scandinavica.

[16]  B. Kleim,et al.  Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication , 2011, Schizophrenia Research.

[17]  Abraham Weizman,et al.  Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study , 2011, Schizophrenia Research.

[18]  P. McGorry,et al.  Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care , 2011, Current opinion in psychiatry.

[19]  L. Boyer,et al.  One or more durations of untreated psychosis? , 2011, Acta Psychiatrica Scandinavica.

[20]  S. Bashir,et al.  Association between Knowledge and Drug Adherence in Patients with Hypertension in Quetta, Pakistan , 2011 .

[21]  J. Menzin,et al.  Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. , 2010, Psychiatric services.

[22]  Robert Kohn,et al.  Epidemiología de los trastornos mentales en América Latina y el Caribe , 2010 .

[23]  L. Boyer,et al.  Factors Associated with Medication Non-Adherence in Patients Suffering from Schizophrenia: A Cross-Sectional Study in a Universal Coverage Health-Care System , 2010 .

[24]  P. Weiden,et al.  The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. , 2009, The Journal of clinical psychiatry.

[25]  J. A. Sacristán,et al.  [Treatment adherence and persistence: causes, consequences and improvement strategies]. , 2009, Atencion primaria.

[26]  T. Gilmer,et al.  Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. , 2009, Psychiatric services.

[27]  J. Lieberman,et al.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. , 2008, The Journal of clinical psychiatry.

[28]  K. H. Gundermann,et al.  Vigencia y desplazamiento de la lengua aymara en Chile , 2007 .

[29]  A. Fu,et al.  Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States , 2007, Current medical research and opinion.

[30]  R. Walden Gender bias in research , 2007, Journal of the Royal Society of Medicine.

[31]  A. Holdcroft Gender bias in research: how does it affect evidence based medicine? , 2007, Journal of the Royal Society of Medicine.

[32]  Jacqueline L Johnson,et al.  Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode , 2006, Schizophrenia Research.

[33]  J. Lieberman,et al.  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls , 2005, Schizophrenia Research.

[34]  Alexander L. Miller,et al.  Defining and assessing adherence to oral antipsychotics: a review of the literature. , 2005, Schizophrenia bulletin.

[35]  Robert Kohn,et al.  Los trastornos mentales en América Latina y el Caribe: asunto prioritario para la salud pública , 2005 .

[36]  H. Nicolini,et al.  A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients , 2005, Schizophrenia Research.

[37]  J. Suvisaari,et al.  Age at onset and cognitive functioning in schizophrenia , 2004, British Journal of Psychiatry.

[38]  R. Rasetti,et al.  Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. , 2004, The Journal of clinical psychiatry.

[39]  F. P. Agraz,et al.  Evaluación de actitudes al medicamento en pacientes con esquizofrenia: propiedades psicométricas de la versión en español del DAI , 2004 .

[40]  Robert F. Reynolds,et al.  Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia , 2004, The Journal of nervous and mental disease.

[41]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[42]  W. Fleischhacker,et al.  Factors influencing compliance in schizophrenia patients. , 2003, The Journal of clinical psychiatry.

[43]  Christian R. Dolder,et al.  Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia , 2003, Schizophrenia Research.

[44]  S. Thomas,et al.  Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. , 2003, British journal of clinical pharmacology.

[45]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[46]  M. Tohen,et al.  Sex differences in clinical response to olanzapine compared with haloperidol , 2002, Psychiatry Research.

[47]  A. Malla,et al.  Duration of untreated psychosis: a critical examination of the concept and its importance , 2001, Psychological Medicine.

[48]  C. Lançon,et al.  Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS) , 2000, Schizophrenia Research.

[49]  M. Razali,et al.  Compliance with treatment in schizophrenia: a drug intervention program in a developing country , 1995, Acta psychiatrica Scandinavica.

[50]  T. Barnes A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[51]  J L Young,et al.  Medication noncompliance in schizophrenia: codification and update. , 1986, The Bulletin of the American Academy of Psychiatry and the Law.

[52]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.

[53]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[54]  Y. Bloch,et al.  P-1278 - Rebelliousness in Patients Suffering From Schizophrenia-spectrum Disorders - a Possible Predictor of Adherence , 2012, European psychiatry.

[55]  K. Zillmann Putting gender on the agenda , 2010, Nature.

[56]  X. Amador,et al.  Poor insight in schizophrenia , 2005, Psychiatric Quarterly.

[57]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[58]  W. Gaebel,et al.  A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. , 2001, Schizophrenia bulletin.

[59]  W S Fenton,et al.  Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.

[60]  Jorge,et al.  Etnografía : sociedades indígenas contemporáneas y su ideología , 1996 .

[61]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[62]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.